---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-26-000023"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:34:30.676469+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance

## Summary
- GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.
- Point of Care revenue $113M (-34% YoY) on weak respiratory season; Labs $353M (-5%); Immunohematology $138M (+8%).
- Full-year 2026 guidance cut: revenue $2.70-2.75B (prev. $2.7-2.9B), adj. EBITDA $615-630M (prev. $630-670M), adj. EPS $1.80-2.00 (prev. $2.00-2.42).
- Acquired LEX Diagnostics in April for ultra-fast point-of-care molecular diagnostics platform.
- U.S. launch of High-Sensitivity Troponin and international rollout of VITROS 450 platform underway.

## SEC filing metadata
- accession: 0001906324-26-000023
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/0001906324-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/qdel-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-26-000023
- JSON: https://secwatch.observer/filing/0001906324-26-000023.json
- Plain text: https://secwatch.observer/filing/0001906324-26-000023.txt

## Key facts
- Earnings Releases
  QuidelOrtho Corp reported first quarter ended March 29, 2026 results: revenue $620 million. Guidance lowered.
  - Period: first quarter ended March 29, 2026
  - Revenue: $620 million
  - Guidance: lowered
  - Result: reported results
  source text: Key First Quarter 2026 Results: (all comparisons are to the prior year period) • Total revenu e was $620 million , as reported ◦ Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/0001906324-26-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.